Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 103

1.

Ferumoxytol in clinical practice: implications for MRI.

McCullough BJ, Kolokythas O, Maki JH, Green DE.

J Magn Reson Imaging. 2013 Jun;37(6):1476-9. doi: 10.1002/jmri.23879. Epub 2012 Oct 23.

PMID:
23097302
[PubMed - indexed for MEDLINE]
2.

Parenteral ferumoxytol interaction with magnetic resonance imaging: a case report, review of the literature and advisory warning.

Schieda N.

Insights Imaging. 2013 Aug;4(4):509-12. doi: 10.1007/s13244-013-0262-8. Epub 2013 Jun 12.

PMID:
23756996
[PubMed]
Free PMC Article
3.

[Focal liver lesions. A comparison between magnetic resonance under base conditions and after a superparamagentic contrast medium].

Finazzo M, Midiri M, Gallo C, Bartolotta TV, Luca A.

Radiol Med. 1998 Jun;95(6):599-607. Italian.

PMID:
9717542
[PubMed - indexed for MEDLINE]
4.

Emerging applications for ferumoxytol as a contrast agent in MRI.

Bashir MR, Bhatti L, Marin D, Nelson RC.

J Magn Reson Imaging. 2014 Jun 30. doi: 10.1002/jmri.24691. [Epub ahead of print]

PMID:
24974785
[PubMed - as supplied by publisher]
5.

The long-lasting effect of ferumoxytol on abdominal magnetic resonance imaging.

Harman A, Chang KJ, Dupuy D, Rintels P.

J Comput Assist Tomogr. 2014 Jul-Aug;38(4):571-3. doi: 10.1097/RCT.0000000000000086.

PMID:
24733001
[PubMed - indexed for MEDLINE]
6.

[Hepatic and hepatocarcinoma magnetic resonance: comparison of the results obtained with paramagnetic (gadolinium) and superparamagnetic (iron oxide particles) contrast media].

Castoldi MC, Fauda V, Scaramuzza D, Vergnaghi D.

Radiol Med. 2000 Sep;100(3):160-7. Italian.

PMID:
11148882
[PubMed - indexed for MEDLINE]
7.

Comparative analysis of ferumoxytol and gadoteridol enhancement using T1- and T2-weighted MRI in neuroimaging.

Hamilton BE, Nesbit GM, Dosa E, Gahramanov S, Rooney B, Nesbit EG, Raines J, Neuwelt EA.

AJR Am J Roentgenol. 2011 Oct;197(4):981-8. doi: 10.2214/AJR.10.5992.

PMID:
21940589
[PubMed - indexed for MEDLINE]
Free PMC Article
8.

Hepatocellular lesions with increased iron uptake on superparamagnetic iron oxide-enhanced magnetic resonance imaging in cirrhosis or chronic hepatitis: comparison of four magnetic resonance sequences for lesion conspicuity.

Tanabe M, Ito K, Shimizu A, Fujita T, Onoda H, Yamatogi S, Washida Y, Matsunaga N.

Magn Reson Imaging. 2009 Jul;27(6):801-6. doi: 10.1016/j.mri.2008.11.006. Epub 2009 Jan 13.

PMID:
19144487
[PubMed - indexed for MEDLINE]
9.

Comparison of two superparamagnetic viral-sized iron oxide particles ferumoxides and ferumoxtran-10 with a gadolinium chelate in imaging intracranial tumors.

Varallyay P, Nesbit G, Muldoon LL, Nixon RR, Delashaw J, Cohen JI, Petrillo A, Rink D, Neuwelt EA.

AJNR Am J Neuroradiol. 2002 Apr;23(4):510-9.

PMID:
11950637
[PubMed - indexed for MEDLINE]
Free Article
10.

The potential of ferumoxytol nanoparticle magnetic resonance imaging, perfusion, and angiography in central nervous system malignancy: a pilot study.

Neuwelt EA, Várallyay CG, Manninger S, Solymosi D, Haluska M, Hunt MA, Nesbit G, Stevens A, Jerosch-Herold M, Jacobs PM, Hoffman JM.

Neurosurgery. 2007 Apr;60(4):601-11; discussion 611-2.

PMID:
17415196
[PubMed - indexed for MEDLINE]
11.

MR imaging in patients with Crohn disease: value of T2- versus T1-weighted gadolinium-enhanced MR sequences with use of an oral superparamagnetic contrast agent.

Maccioni F, Bruni A, Viscido A, Colaiacomo MC, Cocco A, Montesani C, Caprilli R, Marini M.

Radiology. 2006 Feb;238(2):517-30. Epub 2005 Dec 21. Erratum in: Radiology. 2013 Aug;268(2):614.

PMID:
16371574
[PubMed - indexed for MEDLINE]
12.

Hepatocellular carcinoma in cirrhosis: enhancement patterns at dynamic gadolinium- and superparamagnetic iron oxide-enhanced T1-weighted MR imaging.

Lutz AM, Willmann JK, Goepfert K, Marincek B, Weishaupt D.

Radiology. 2005 Nov;237(2):520-8. Epub 2005 Sep 28.

PMID:
16192317
[PubMed - indexed for MEDLINE]
13.

[Magnetic resonance imaging of hepatic focal lesions: dynamic contrastographic evaluation with gadolinium versus reticulo-endothelial hepato-specific contrast media].

Di Cesare E, Cariello G, Barile A, Sabatini M, Michelini O, Erriquez D, Masciocchi C.

Radiol Med. 2000 Oct;100(4):245-50. Italian.

PMID:
11155451
[PubMed - indexed for MEDLINE]
14.

Blood-pool MR contrast material for detection and characterization of focal hepatic lesions: initial clinical experience with ultrasmall superparamagnetic iron oxide (AMI-227).

Saini S, Edelman RR, Sharma P, Li W, Mayo-Smith W, Slater GJ, Eisenberg PJ, Hahn PF.

AJR Am J Roentgenol. 1995 May;164(5):1147-52.

PMID:
7717222
[PubMed - indexed for MEDLINE]
15.

Imaging of macrophages in soft-tissue infection in rats: relationship between ultrasmall superparamagnetic iron oxide dose and MR signal characteristics.

Lutz AM, Weishaupt D, Persohn E, Goepfert K, Froehlich J, Sasse B, Gottschalk J, Marincek B, Kaim AH.

Radiology. 2005 Mar;234(3):765-75. Epub 2005 Jan 21.

PMID:
15665219
[PubMed - indexed for MEDLINE]
16.

MRI assessment of hepatic iron clearance rates after USPIO administration in healthy adults.

Storey P, Lim RP, Chandarana H, Rosenkrantz AB, Kim D, Stoffel DR, Lee VS.

Invest Radiol. 2012 Dec;47(12):717-24. doi: 10.1097/RLI.0b013e31826dc151.

PMID:
23070094
[PubMed - indexed for MEDLINE]
17.

Sequential use of ferumoxide particles and gadolinium chelate for the evaluation of focal liver lesions on MRI.

Semelka RC, Lee JK, Worawattanakul S, Noone TC, Patt RH, Ascher SM.

J Magn Reson Imaging. 1998 May-Jun;8(3):670-4.

PMID:
9626884
[PubMed - indexed for MEDLINE]
18.

Ultrasmall superparamagnetic iron oxide nanoparticles conjugated with Ile-Pro-Leu-Pro-Phe-Tyr-Asn.

Leung K.

Molecular Imaging and Contrast Agent Database (MICAD) [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2004-2013.
2010 Feb 23 [updated 2010 Mar 25].

PMID:
20641977
[PubMed]
Books & Documents
19.

Polyethylene glycol–coated and folic acid–conjugated superparamagnetic iron oxide nanoparticles.

Shan L.

Molecular Imaging and Contrast Agent Database (MICAD) [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2004-2013.
2009 Sep 30 [updated 2009 Nov 12].

PMID:
20641868
[PubMed]
Books & Documents
20.

Superparamagnetic iron oxide nanoparticles (SPION) stabilized by alginate.

Shan L.

Molecular Imaging and Contrast Agent Database (MICAD) [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2004-2013.
2009 Oct 13 [updated 2009 Nov 30].

PMID:
20641831
[PubMed]
Books & Documents

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk